

**Table 14.3.4.1.2.1**  
**PF-06410293 Protocol B5381001**  
**Laboratory Data Absolute Values - Safety Analysis Set**  
**Parameter: Blood Urea Nitrogen (mg/dL)**

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
<b>Study Day</b>					
Baseline	n	69	71	70	210
	Mean	14.86	15.06	15.13	15.01
	SD	4.288	3.320	3.897	3.834
	Median	15.00	15.00	15.00	15.00
	Min	6.00	8.00	4.00	4.00
	Max	24.00	24.00	26.00	26.00
Day4	n	69	71	70	210
	Mean	13.91	13.90	13.90	13.90
	SD	3.203	2.982	3.061	3.067
	Median	13.00	14.00	14.00	14.00
	Min	7.00	8.00	7.00	7.00
	Max	23.00	22.00	21.00	23.00
Day8	n	69	71	70	210
	Mean	14.19	14.11	14.00	14.10
	SD	3.074	3.096	2.735	2.960
	Median	14.00	13.00	14.00	14.00
	Min	8.00	9.00	8.00	8.00
	Max	21.00	24.00	21.00	24.00

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)

090177e18e74aa74\Final\Final On: 30-May-2018 05:31 (GMT)

**Table 14.3.4.1.2.1**  
**PF-06410293 Protocol B5381001**  
**Laboratory Data Absolute Values - Safety Analysis Set**  
**Parameter: Blood Urea Nitrogen (mg/dL)**

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
<b>Study Day</b>					
Day15	n	68	71	69	208
	Mean	14.53	15.39	15.28	15.07
	SD	3.712	3.662	4.072	3.820
	Median	15.00	15.00	15.00	15.00
	Min	8.00	8.00	6.00	6.00
	Max	23.00	24.00	26.00	26.00
Day29	n	67	70	70	207
	Mean	14.91	15.93	16.29	15.72
	SD	3.246	4.348	4.553	4.122
	Median	15.00	15.50	15.50	15.00
	Min	7.00	8.00	5.00	5.00
	Max	24.00	26.00	27.00	27.00
Day43	n	67	71	69	207
	Mean	15.12	15.89	15.43	15.49
	SD	3.711	4.435	3.894	4.025
	Median	15.00	15.00	15.00	15.00
	Min	8.00	7.00	7.00	7.00
	Max	26.00	29.00	27.00	29.00

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)

090177e18e74aa74\Final\Final On: 30-May-2018 05:31 (GMT)

**Table 14.3.4.1.2.1**  
**PF-06410293 Protocol B5381001**  
**Laboratory Data Absolute Values - Safety Analysis Set**  
**Parameter: Blood Urea Nitrogen (mg/dL)**

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
<b>Study Day</b>					
Day71	n	69	71	70	210
	Mean	15.43	14.93	15.57	15.31
	SD	4.210	3.785	3.854	3.943
	Median	15.00	14.00	15.00	15.00
	Min	8.00	8.00	9.00	8.00
	Max	26.00	23.00	27.00	27.00

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)

**Table 14.3.4.1.2.1**  
**PF-06410293 Protocol B5381001**  
**Laboratory Data Absolute Values - Safety Analysis Set**  
**Parameter: Urea (mg/dL)**

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
<b>Study Day</b>					
Baseline	n	41	42	42	125
	Mean	32.51	33.36	35.29	33.73
	SD	9.119	6.945	7.781	8.009
	Median	31.00	33.00	33.50	33.00
	Min	14.00	22.00	23.00	14.00
	Max	52.00	48.00	56.00	56.00
Day4	n	41	42	42	125
	Mean	31.71	32.00	32.12	31.94
	SD	7.474	5.835	5.989	6.416
	Median	30.00	31.50	32.00	32.00
	Min	16.00	21.00	16.00	16.00
	Max	49.00	47.00	46.00	49.00
Day8	n	41	42	42	125
	Mean	31.90	31.95	32.00	31.95
	SD	6.793	6.814	5.640	6.384
	Median	29.00	29.50	31.50	31.00
	Min	21.00	22.00	20.00	20.00
	Max	46.00	51.00	46.00	51.00

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)

090177e18e74aa74\Final\Final On: 30-May-2018 05:31 (GMT)

**Table 14.3.4.1.2.1**  
**PF-06410293 Protocol B5381001**  
**Laboratory Data Absolute Values - Safety Analysis Set**  
**Parameter: Urea (mg/dL)**

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
<b>Study Day</b>					
Day15	n	40	42	42	124
	Mean	31.53	34.74	34.36	33.57
	SD	7.867	7.480	7.496	7.684
	Median	32.00	34.00	32.00	33.00
	Min	17.00	20.00	21.00	17.00
	Max	50.00	51.00	52.00	52.00
Day29	n	40	42	42	124
	Mean	33.03	35.00	37.57	35.23
	SD	7.691	8.599	8.620	8.464
	Median	33.00	34.00	35.50	34.00
	Min	15.00	20.00	25.00	15.00
	Max	52.00	53.00	57.00	57.00
Day43	n	39	42	41	122
	Mean	33.05	36.02	34.90	34.70
	SD	7.616	9.296	7.529	8.230
	Median	33.00	34.50	36.00	34.00
	Min	18.00	23.00	22.00	18.00
	Max	46.00	62.00	58.00	62.00

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)

**Table 14.3.4.1.2.1**  
**PF-06410293 Protocol B5381001**  
**Laboratory Data Absolute Values - Safety Analysis Set**  
**Parameter: Urea (mg/dL)**

		<b>Adalimumab-Pfizer (N=69)</b>	<b>Adalimumab-US (N=71)</b>	<b>Adalimumab-EU (N=70)</b>	<b>Total (N=210)</b>
<b>Study Day</b>					
Day71	n	41	42	42	125
	Mean	33.71	33.12	34.79	33.87
	SD	9.626	7.718	7.452	8.273
	Median	33.00	32.00	34.50	33.00
	Min	17.00	17.00	23.00	17.00
	Max	56.00	48.00	52.00	56.00

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)

**Table 14.3.4.1.2.1**  
**PF-06410293 Protocol B5381001**  
**Laboratory Data Absolute Values - Safety Analysis Set**  
**Parameter: Creatinine (mg/dL)**

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
<b>Study Day</b>					
Baseline	n	69	71	70	210
	Mean	0.97	0.99	0.96	0.97
	SD	0.133	0.163	0.126	0.141
	Median	1.00	1.00	0.90	1.00
	Min	0.70	0.60	0.70	0.60
	Max	1.40	1.40	1.30	1.40
Day4	n	69	71	70	210
	Mean	0.98	0.98	0.96	0.97
	SD	0.152	0.169	0.139	0.153
	Median	1.00	1.00	0.95	1.00
	Min	0.70	0.70	0.60	0.60
	Max	1.40	1.50	1.40	1.50
Day8	n	69	71	70	210
	Mean	0.97	0.98	0.96	0.97
	SD	0.138	0.162	0.135	0.145
	Median	1.00	1.00	0.90	1.00
	Min	0.70	0.70	0.70	0.70
	Max	1.40	1.50	1.40	1.50

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)

**Table 14.3.4.1.2.1**  
**PF-06410293 Protocol B5381001**  
**Laboratory Data Absolute Values - Safety Analysis Set**  
**Parameter: Creatinine (mg/dL)**

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
<b>Study Day</b>					
Day15	n	68	71	69	208
	Mean	1.00	0.99	0.99	0.99
	SD	0.148	0.169	0.131	0.150
	Median	1.00	1.00	1.00	1.00
	Min	0.70	0.70	0.70	0.70
	Max	1.40	1.60	1.30	1.60
Day29	n	67	70	70	207
	Mean	0.97	0.99	0.98	0.98
	SD	0.151	0.163	0.131	0.149
	Median	1.00	1.00	1.00	1.00
	Min	0.70	0.70	0.70	0.70
	Max	1.30	1.50	1.40	1.50
Day43	n	67	71	69	207
	Mean	1.00	1.01	0.97	0.99
	SD	0.142	0.167	0.132	0.148
	Median	1.00	1.00	1.00	1.00
	Min	0.70	0.70	0.60	0.60
	Max	1.40	1.50	1.30	1.50

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)



**Table 14.3.4.1.2.1**  
**PF-06410293 Protocol B5381001**  
**Laboratory Data Absolute Values - Safety Analysis Set**  
**Parameter: Creatinine (mg/dL)**

		<b>Adalimumab-Pfizer (N=69)</b>	<b>Adalimumab-US (N=71)</b>	<b>Adalimumab-EU (N=70)</b>	<b>Total (N=210)</b>
<b>Study Day</b>					
Day71	n	69	71	70	210
	Mean	0.99	1.00	0.99	0.99
	SD	0.133	0.174	0.139	0.149
	Median	1.00	1.00	1.00	1.00
	Min	0.80	0.70	0.70	0.70
	Max	1.30	1.50	1.40	1.50

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)

**Table 14.3.4.1.2.1**  
**PF-06410293 Protocol B5381001**  
**Laboratory Data Absolute Values - Safety Analysis Set**  
**Parameter: Urate (mg/dL)**

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Baseline	n	69	71	70	210
	Mean	5.81	5.94	5.77	5.84
	SD	0.998	1.045	0.961	1.000
	Median	5.70	6.10	5.70	5.80
	Min	3.80	3.40	3.90	3.40
	Max	8.20	8.70	8.10	8.70
Day4	n	69	71	70	210
	Mean	5.75	5.80	5.67	5.74
	SD	1.114	0.981	0.950	1.013
	Median	5.60	5.80	5.60	5.70
	Min	3.60	4.10	3.50	3.50
	Max	9.10	7.80	7.90	9.10
Day8	n	69	71	70	210
	Mean	5.65	5.71	5.60	5.65
	SD	0.956	0.898	0.898	0.914
	Median	5.50	5.60	5.45	5.50
	Min	3.40	3.80	3.50	3.40
	Max	8.40	8.30	8.70	8.70

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)

**Table 14.3.4.1.2.1**  
**PF-06410293 Protocol B5381001**  
**Laboratory Data Absolute Values - Safety Analysis Set**  
**Parameter: Urate (mg/dL)**

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
<b>Study Day</b>					
Day15	n	68	71	69	208
	Mean	5.94	6.14	5.93	6.00
	SD	0.951	1.003	0.899	0.952
	Median	5.80	6.20	5.90	5.90
	Min	4.30	3.70	3.90	3.70
	Max	8.70	9.90	7.80	9.90
Day29	n	67	70	70	207
	Mean	5.89	6.03	5.90	5.94
	SD	0.955	1.077	1.021	1.017
	Median	5.80	6.00	5.90	5.90
	Min	3.80	4.10	3.80	3.80
	Max	8.00	8.70	9.00	9.00
Day43	n	67	71	69	207
	Mean	5.95	6.08	5.85	5.96
	SD	1.071	1.059	0.985	1.038
	Median	5.90	6.20	5.90	6.00
	Min	3.90	4.20	3.50	3.50
	Max	9.10	9.30	8.00	9.30

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)

**Table 14.3.4.1.2.1**  
**PF-06410293 Protocol B5381001**  
**Laboratory Data Absolute Values - Safety Analysis Set**  
**Parameter: Urate (mg/dL)**

		<b>Adalimumab-Pfizer (N=69)</b>	<b>Adalimumab-US (N=71)</b>	<b>Adalimumab-EU (N=70)</b>	<b>Total (N=210)</b>
<b>Study Day</b>					
Day71	n	69	71	70	210
	Mean	5.90	6.04	5.81	5.92
	SD	1.021	1.205	0.898	1.049
	Median	5.70	6.00	5.80	5.80
	Min	3.70	3.70	3.60	3.60
	Max	8.40	10.70	7.70	10.70

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)

**Table 14.3.4.1.2.1**  
**PF-06410293 Protocol B5381001**  
**Laboratory Data Absolute Values - Safety Analysis Set**  
**Parameter: Sodium (Meq/L)**

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
<b>Study Day</b>					
Baseline	n	69	71	70	210
	Mean	140.74	140.49	140.74	140.66
	SD	2.153	1.999	1.916	2.018
	Median	141.00	140.00	141.00	141.00
	Min	134.00	136.00	137.00	134.00
	Max	144.00	146.00	146.00	146.00
Day4	n	69	71	70	210
	Mean	140.80	140.72	140.60	140.70
	SD	1.605	1.532	1.663	1.595
	Median	141.00	141.00	140.50	141.00
	Min	137.00	138.00	137.00	137.00
	Max	144.00	145.00	146.00	146.00
Day8	n	69	71	70	210
	Mean	141.22	141.18	141.16	141.19
	SD	1.773	2.002	1.766	1.843
	Median	141.00	141.00	141.00	141.00
	Min	137.00	136.00	138.00	136.00
	Max	146.00	146.00	146.00	146.00

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)

**Table 14.3.4.1.2.1**  
**PF-06410293 Protocol B5381001**  
**Laboratory Data Absolute Values - Safety Analysis Set**  
**Parameter: Sodium (Meq/L)**

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
<b>Study Day</b>					
Day15	n	68	71	69	208
	Mean	141.16	140.45	140.97	140.86
	SD	1.617	1.911	1.886	1.828
	Median	141.00	140.00	141.00	141.00
	Min	137.00	135.00	137.00	135.00
	Max	145.00	146.00	146.00	146.00
Day29	n	67	70	70	207
	Mean	140.67	140.44	140.99	140.70
	SD	1.837	2.040	1.907	1.935
	Median	141.00	141.00	141.00	141.00
	Min	136.00	134.00	136.00	134.00
	Max	145.00	145.00	147.00	147.00
Day43	n	67	71	69	207
	Mean	140.58	140.21	140.25	140.34
	SD	1.725	1.912	1.936	1.860
	Median	141.00	140.00	140.00	140.00
	Min	136.00	134.00	135.00	134.00
	Max	144.00	145.00	144.00	145.00

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)

**Table 14.3.4.1.2.1**  
**PF-06410293 Protocol B5381001**  
**Laboratory Data Absolute Values - Safety Analysis Set**  
**Parameter: Sodium (Meq/L)**

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
<b>Study Day</b>					
Day71	n	69	71	70	210
	Mean	140.80	140.15	140.64	140.53
	SD	1.677	1.969	1.737	1.812
	Median	141.00	140.00	141.00	140.00
	Min	138.00	135.00	136.00	135.00
	Max	147.00	147.00	145.00	147.00

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)

**Table 14.3.4.1.2.1**  
**PF-06410293 Protocol B5381001**  
**Laboratory Data Absolute Values - Safety Analysis Set**  
**Parameter: Potassium (Meq/L)**

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Baseline	n	69	71	70	210
	Mean	4.27	4.28	4.29	4.28
	SD	0.295	0.336	0.311	0.313
	Median	4.30	4.20	4.30	4.25
	Min	3.70	3.60	3.70	3.60
	Max	5.00	5.00	5.00	5.00
Day4	n	69	71	70	210
	Mean	4.44	4.43	4.47	4.45
	SD	0.262	0.359	0.314	0.313
	Median	4.40	4.40	4.40	4.40
	Min	4.00	3.80	3.90	3.80
	Max	5.10	5.60	5.30	5.60
Day8	n	69	71	70	210
	Mean	4.48	4.51	4.51	4.50
	SD	0.310	0.331	0.315	0.318
	Median	4.40	4.50	4.50	4.50
	Min	3.90	3.90	3.90	3.90
	Max	5.30	5.50	5.40	5.50

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)



**Table 14.3.4.1.2.1**  
**PF-06410293 Protocol B5381001**  
**Laboratory Data Absolute Values - Safety Analysis Set**  
**Parameter: Potassium (Meq/L)**

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
<b>Study Day</b>					
Day15	n	68	71	69	208
	Mean	4.31	4.38	4.43	4.37
	SD	0.293	0.367	0.317	0.330
	Median	4.30	4.40	4.40	4.35
	Min	3.50	3.60	3.80	3.50
	Max	5.00	5.40	5.30	5.40
Day29	n	67	70	70	207
	Mean	4.26	4.32	4.28	4.29
	SD	0.295	0.320	0.360	0.326
	Median	4.20	4.30	4.30	4.30
	Min	3.70	3.70	3.30	3.30
	Max	5.20	5.20	5.10	5.20
Day43	n	67	71	69	207
	Mean	4.38	4.31	4.34	4.34
	SD	0.338	0.359	0.395	0.364
	Median	4.30	4.30	4.30	4.30
	Min	3.80	3.40	3.10	3.10
	Max	5.90	5.60	5.70	5.90

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)

**Table 14.3.4.1.2.1**  
**PF-06410293 Protocol B5381001**  
**Laboratory Data Absolute Values - Safety Analysis Set**  
**Parameter: Potassium (Meq/L)**

		<b>Adalimumab-Pfizer (N=69)</b>	<b>Adalimumab-US (N=71)</b>	<b>Adalimumab-EU (N=70)</b>	<b>Total (N=210)</b>
<b>Study Day</b>					
Day71	n	69	71	70	210
	Mean	4.32	4.27	4.34	4.31
	SD	0.337	0.382	0.313	0.345
	Median	4.30	4.20	4.30	4.30
	Min	3.60	3.50	3.60	3.50
	Max	5.20	5.50	5.40	5.50

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)

**Table 14.3.4.1.2.1**  
**PF-06410293 Protocol B5381001**  
**Laboratory Data Absolute Values - Safety Analysis Set**  
**Parameter: Chloride (Meq/L)**

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Baseline	n	69	71	70	210
	Mean	104.13	103.69	103.76	103.86
	SD	2.885	2.556	2.109	2.530
	Median	104.00	104.00	104.00	104.00
	Min	99.00	98.00	99.00	98.00
	Max	111.00	109.00	110.00	111.00
Day4	n	69	71	70	210
	Mean	104.52	104.25	104.56	104.44
	SD	2.883	2.260	2.630	2.592
	Median	104.00	104.00	104.00	104.00
	Min	100.00	99.00	99.00	99.00
	Max	112.00	110.00	114.00	114.00
Day8	n	69	71	70	210
	Mean	104.19	104.04	103.91	104.05
	SD	2.729	2.469	2.495	2.556
	Median	104.00	104.00	104.00	104.00
	Min	97.00	99.00	99.00	97.00
	Max	110.00	110.00	110.00	110.00

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)

**Table 14.3.4.1.2.1**  
**PF-06410293 Protocol B5381001**  
**Laboratory Data Absolute Values - Safety Analysis Set**  
**Parameter: Chloride (Meq/L)**

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
<b>Study Day</b>					
Day15	n	68	71	69	208
	Mean	104.59	104.23	104.49	104.43
	SD	2.546	2.218	2.266	2.340
	Median	104.00	104.00	104.00	104.00
	Min	99.00	99.00	98.00	98.00
	Max	111.00	111.00	110.00	111.00
Day29	n	67	70	70	207
	Mean	104.51	103.97	104.41	104.29
	SD	3.121	2.473	2.435	2.685
	Median	104.00	104.00	105.00	104.00
	Min	98.00	98.00	98.00	98.00
	Max	114.00	110.00	109.00	114.00
Day43	n	67	71	69	207
	Mean	104.60	104.32	104.29	104.40
	SD	3.105	3.471	2.896	3.157
	Median	105.00	104.00	104.00	104.00
	Min	99.00	97.00	95.00	95.00
	Max	112.00	116.00	111.00	116.00

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)

**Table 14.3.4.1.2.1**  
**PF-06410293 Protocol B5381001**  
**Laboratory Data Absolute Values - Safety Analysis Set**  
**Parameter: Chloride (Meq/L)**

		<b>Adalimumab-Pfizer (N=69)</b>	<b>Adalimumab-US (N=71)</b>	<b>Adalimumab-EU (N=70)</b>	<b>Total (N=210)</b>
<b>Study Day</b>					
Day71	n	69	71	70	210
	Mean	104.54	103.79	104.41	104.24
	SD	2.943	2.863	2.411	2.755
	Median	105.00	104.00	104.00	104.00
	Min	99.00	97.00	99.00	97.00
	Max	112.00	111.00	110.00	112.00

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)

**Table 14.3.4.1.2.1**  
**PF-06410293 Protocol B5381001**  
**Laboratory Data Absolute Values - Safety Analysis Set**  
**Parameter: Calcium (mg/dL)**

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
<b>Study Day</b>					
Baseline	n	69	71	70	210
	Mean	9.66	9.66	9.69	9.67
	SD	0.330	0.339	0.363	0.343
	Median	9.60	9.60	9.70	9.65
	Min	8.80	8.90	8.80	8.80
	Max	10.40	10.70	10.50	10.70
Day4	n	69	71	70	210
	Mean	9.69	9.63	9.69	9.67
	SD	0.276	0.382	0.336	0.334
	Median	9.70	9.60	9.70	9.70
	Min	9.10	8.70	8.70	8.70
	Max	10.30	10.40	10.60	10.60
Day8	n	69	71	70	210
	Mean	9.76	9.75	9.76	9.76
	SD	0.323	0.334	0.376	0.344
	Median	9.70	9.70	9.80	9.70
	Min	9.10	9.00	8.90	8.90
	Max	10.60	10.50	10.70	10.70

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)

**Table 14.3.4.1.2.1**  
**PF-06410293 Protocol B5381001**  
**Laboratory Data Absolute Values - Safety Analysis Set**  
**Parameter: Calcium (mg/dL)**

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
<b>Study Day</b>					
Day15	n	68	71	69	208
	Mean	9.65	9.69	9.65	9.66
	SD	0.369	0.370	0.367	0.367
	Median	9.70	9.70	9.60	9.70
	Min	8.70	8.80	8.80	8.70
	Max	10.40	10.50	10.30	10.50
Day29	n	67	70	70	207
	Mean	9.62	9.68	9.68	9.66
	SD	0.360	0.353	0.382	0.365
	Median	9.70	9.60	9.70	9.70
	Min	8.90	8.90	8.80	8.80
	Max	10.30	10.60	10.60	10.60
Day43	n	67	71	69	207
	Mean	9.74	9.68	9.68	9.70
	SD	0.306	0.329	0.343	0.326
	Median	9.70	9.70	9.70	9.70
	Min	9.10	9.00	8.60	8.60
	Max	10.70	10.40	10.40	10.70

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)

**Table 14.3.4.1.2.1**  
**PF-06410293 Protocol B5381001**  
**Laboratory Data Absolute Values - Safety Analysis Set**  
**Parameter: Calcium (mg/dL)**

		<b>Adalimumab-Pfizer (N=69)</b>	<b>Adalimumab-US (N=71)</b>	<b>Adalimumab-EU (N=70)</b>	<b>Total (N=210)</b>
<b>Study Day</b>					
Day71	n	69	71	70	210
	Mean	9.73	9.70	9.72	9.72
	SD	0.334	0.347	0.311	0.329
	Median	9.70	9.70	9.70	9.70
	Min	9.00	8.70	9.00	8.70
	Max	10.60	10.60	10.50	10.60

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)



**Table 14.3.4.1.2.1**  
**PF-06410293 Protocol B5381001**  
**Laboratory Data Absolute Values - Safety Analysis Set**  
**Parameter: Bicarbonate (Meq/L)**

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
<b>Study Day</b>					
Baseline	n	69	71	70	210
	Mean	28.45	28.48	28.40	28.44
	SD	2.323	2.229	2.183	2.235
	Median	28.00	28.00	29.00	28.50
	Min	23.00	24.00	24.00	23.00
	Max	34.00	33.00	33.00	34.00
Day4	n	69	71	70	210
	Mean	28.93	28.44	28.90	28.75
	SD	2.074	2.103	2.188	2.124
	Median	29.00	28.00	29.00	29.00
	Min	24.00	24.00	25.00	24.00
	Max	33.00	34.00	36.00	36.00
Day8	n	69	71	70	210
	Mean	29.60	29.81	29.67	29.69
	SD	1.995	2.328	2.145	2.153
	Median	30.00	30.00	30.00	30.00
	Min	23.20	22.90	24.00	22.90
	Max	34.00	35.00	34.00	35.00

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)

**Table 14.3.4.1.2.1**  
**PF-06410293 Protocol B5381001**  
**Laboratory Data Absolute Values - Safety Analysis Set**  
**Parameter: Bicarbonate (Meq/L)**

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
<b>Study Day</b>					
Day15	n	68	71	69	208
	Mean	29.13	28.54	28.71	28.79
	SD	2.387	2.323	2.474	2.396
	Median	29.00	29.00	29.00	29.00
	Min	23.00	24.00	22.00	22.00
	Max	34.00	34.00	34.00	34.00
Day29	n	67	70	70	207
	Mean	28.49	28.36	28.36	28.40
	SD	2.572	2.384	2.057	2.334
	Median	29.00	28.00	29.00	29.00
	Min	23.00	21.00	23.00	21.00
	Max	33.00	34.00	33.00	34.00
Day43	n	67	71	69	207
	Mean	28.88	28.48	28.46	28.60
	SD	1.981	2.183	2.423	2.203
	Median	29.00	29.00	29.00	29.00
	Min	24.00	23.00	23.00	23.00
	Max	32.00	32.00	34.00	34.00

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)

**Table 14.3.4.1.2.1**  
**PF-06410293 Protocol B5381001**  
**Laboratory Data Absolute Values - Safety Analysis Set**  
**Parameter: Bicarbonate (Meq/L)**

		<b>Adalimumab-Pfizer (N=69)</b>	<b>Adalimumab-US (N=71)</b>	<b>Adalimumab-EU (N=70)</b>	<b>Total (N=210)</b>
<b>Study Day</b>					
Day71	n	69	71	70	210
	Mean	28.64	28.62	28.44	28.57
	SD	1.807	1.751	1.862	1.801
	Median	29.00	29.00	29.00	29.00
	Min	24.00	24.00	24.00	24.00
	Max	32.00	33.00	32.00	33.00

090177e18e74aa74\Final\Final On: 30-May-2018 05:31 (GMT)

Baseline is defined as the most recent measurement prior to dosing.  
 If more than one test fall into the same window, then the one closer to the target day will be selected for the window.  
 If two tests have equal distance to the target day, then the later one will be used.  
 Study Day is based on time windows.  
 Lab results in standard units have been used in the presentation.

**Table 14.3.4.1.2.1**  
**PF-06410293 Protocol B5381001**  
**Laboratory Data Absolute Values - Safety Analysis Set**  
**Parameter: pH**

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Baseline	n	69	71	70	210
	Mean	6.14	5.93	5.91	5.99
	SD	0.907	0.762	0.812	0.831
	Median	6.00	6.00	6.00	6.00
	Min	5.00	5.00	5.00	5.00
	Max	8.00	8.00	8.00	8.00
Day4	n	0	1	1	2
	Mean	-	6.00	5.50	5.75
	SD	-	-	-	0.354
	Median	-	6.00	5.50	5.75
	Min	-	6.00	5.50	5.50
	Max	-	6.00	5.50	6.00
Day8	n	69	71	70	210
	Mean	5.55	5.56	5.56	5.56
	SD	0.557	0.609	0.528	0.563
	Median	5.50	5.50	5.50	5.50
	Min	5.00	5.00	5.00	5.00
	Max	7.00	7.50	7.00	7.50

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)

**Table 14.3.4.1.2.1**  
**PF-06410293 Protocol B5381001**  
**Laboratory Data Absolute Values - Safety Analysis Set**  
**Parameter: pH**

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
<b>Study Day</b>					
Day15	n	1	1	0	2
	Mean	6.00	7.00	-	6.50
	SD	-	-	-	0.707
	Median	6.00	7.00	-	6.50
	Min	6.00	7.00	-	6.00
	Max	6.00	7.00	-	7.00
Day29	n	67	70	69	206
	Mean	5.75	5.81	5.75	5.77
	SD	0.698	0.753	0.726	0.723
	Median	6.00	6.00	6.00	6.00
	Min	5.00	5.00	5.00	5.00
	Max	7.00	8.50	8.00	8.50
Day43	n	67	71	69	207
	Mean	5.69	5.74	5.89	5.78
	SD	0.733	0.801	0.822	0.788
	Median	5.50	5.50	6.00	6.00
	Min	5.00	5.00	5.00	5.00
	Max	8.00	8.50	8.00	8.50

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)

**Table 14.3.4.1.2.1**  
**PF-06410293 Protocol B5381001**  
**Laboratory Data Absolute Values - Safety Analysis Set**  
**Parameter: pH**

		<b>Adalimumab-Pfizer (N=69)</b>	<b>Adalimumab-US (N=71)</b>	<b>Adalimumab-EU (N=70)</b>	<b>Total (N=210)</b>
<b>Study Day</b>					
Day71	n	69	71	70	210
	Mean	5.88	5.81	5.81	5.84
	SD	0.862	0.678	0.753	0.764
	Median	6.00	6.00	6.00	6.00
	Min	5.00	5.00	5.00	5.00
	Max	8.00	7.00	8.00	8.00

090177e18e74aa74\Final\Final On: 30-May-2018 05:31 (GMT)

Baseline is defined as the most recent measurement prior to dosing.  
 If more than one test fall into the same window, then the one closer to the target day will be selected for the window.  
 If two tests have equal distance to the target day, then the later one will be used.  
 Study Day is based on time windows.  
 Lab results in standard units have been used in the presentation.

**Table 14.3.4.1.2.1**  
**PF-06410293 Protocol B5381001**  
**Laboratory Data Absolute Values - Safety Analysis Set**  
**Parameter: Glucose (mg/dL)**

		<b>Adalimumab-Pfizer (N=69)</b>	<b>Adalimumab-US (N=71)</b>	<b>Adalimumab-EU (N=70)</b>	<b>Total (N=210)</b>
<b>Study Day</b>					
Baseline	n	69	71	70	210
	Mean	88.58	88.28	87.50	88.12
	SD	7.521	8.283	6.292	7.393
	Median	88.00	87.00	88.00	87.00
	Min	72.00	71.00	75.00	71.00
	Max	111.00	117.00	104.00	117.00
Day4	n	69	71	70	210
	Mean	86.93	87.68	87.27	87.30
	SD	5.867	6.033	6.295	6.047
	Median	86.00	87.00	87.00	87.00
	Min	76.00	73.00	76.00	73.00
	Max	109.00	106.00	106.00	109.00
Day8	n	69	71	70	210
	Mean	85.68	85.46	86.29	85.81
	SD	5.069	5.121	5.395	5.184
	Median	85.00	86.00	86.00	85.00
	Min	75.00	74.00	78.00	74.00
	Max	100.00	96.00	105.00	105.00

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)

**Table 14.3.4.1.2.1**  
**PF-06410293 Protocol B5381001**  
**Laboratory Data Absolute Values - Safety Analysis Set**  
**Parameter: Glucose (mg/dL)**

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
<b>Study Day</b>					
Day15	n	68	71	69	208
	Mean	91.96	91.03	90.33	91.10
	SD	8.612	8.389	7.567	8.188
	Median	92.00	91.00	90.00	91.00
	Min	76.00	74.00	77.00	74.00
	Max	123.00	114.00	114.00	123.00
Day29	n	67	70	70	207
	Mean	91.97	91.10	91.44	91.50
	SD	7.441	8.015	9.111	8.197
	Median	93.00	91.00	90.50	92.00
	Min	73.00	75.00	62.00	62.00
	Max	108.00	108.00	122.00	122.00
Day43	n	67	71	69	207
	Mean	92.12	92.37	90.36	91.62
	SD	8.065	18.014	7.837	12.336
	Median	93.00	91.00	90.00	91.00
	Min	74.00	74.00	71.00	71.00
	Max	117.00	225.00	115.00	225.00

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)



**Table 14.3.4.1.2.1**  
**PF-06410293 Protocol B5381001**  
**Laboratory Data Absolute Values - Safety Analysis Set**  
**Parameter: Glucose (mg/dL)**

		<b>Adalimumab-Pfizer (N=69)</b>	<b>Adalimumab-US (N=71)</b>	<b>Adalimumab-EU (N=70)</b>	<b>Total (N=210)</b>
<b>Study Day</b>					
Day71	n	69	71	70	210
	Mean	89.59	91.08	90.19	90.30
	SD	7.777	8.419	9.333	8.518
	Median	90.00	91.00	90.00	90.00
	Min	69.00	74.00	58.00	58.00
	Max	107.00	110.00	116.00	116.00

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)

**Table 14.3.4.1.2.2**  
**PF-06410293 Protocol B5381001**  
**Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set**  
**Parameter: Hemoglobin (g/dL)**

		<b>Adalimumab-Pfizer (N=69)</b>	<b>Adalimumab-US (N=71)</b>	<b>Adalimumab-EU (N=70)</b>	<b>Total (N=210)</b>
<b>Study Day</b>					
Baseline	n	69	71	70	210
	Mean	14.66	14.99	14.94	14.86
	SD	0.829	0.920	0.936	0.904
	Median	14.70	15.00	15.00	14.90
	Min	12.90	12.80	11.70	11.70
	Max	16.30	17.40	16.90	17.40
Day4	n	69	71	70	210
	Mean	0.53	0.35	0.27	0.38
	SD	0.696	0.512	0.612	0.617
	Median	0.60	0.50	0.30	0.40
	Min	-0.90	-1.00	-0.90	-1.00
	Max	2.20	1.30	1.60	2.20
Day8	n	69	71	70	210
	Mean	0.52	0.41	0.36	0.43
	SD	0.661	0.428	0.542	0.552
	Median	0.50	0.40	0.40	0.40
	Min	-0.90	-0.80	-1.10	-1.10
	Max	2.30	1.40	1.80	2.30

Baseline is defined as the most recent measurement prior to dosing.  
 If more than one test fall into the same window, then the one closer to the target day will be selected for the window.  
 If two tests have equal distance to the target day, then the later one will be used.  
 Study Day is based on time windows.  
 Lab results in standard units have been used in the presentation.

090177e18e74aa75\Final\Final On: 30-May-2018 05:31 (GMT)

**Table 14.3.4.1.2.2**  
**PF-06410293 Protocol B5381001**  
**Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set**  
**Parameter: Hemoglobin (g/dL)**

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
<b>Study Day</b>					
Day15	n	68	71	69	208
	Mean	0.04	0.03	-0.08	-0.00
	SD	0.586	0.611	0.572	0.590
	Median	0.00	0.10	0.00	0.00
	Min	-1.70	-1.50	-1.60	-1.70
	Max	1.50	1.30	1.00	1.50
Day29	n	67	70	70	207
	Mean	0.13	0.13	0.11	0.12
	SD	0.665	0.587	0.654	0.633
	Median	0.00	0.20	0.20	0.10
	Min	-1.30	-1.30	-1.80	-1.80
	Max	2.50	1.30	1.70	2.50
Day43	n	67	71	69	207
	Mean	0.33	0.12	0.06	0.17
	SD	0.746	0.650	0.674	0.696
	Median	0.40	0.10	0.00	0.10
	Min	-1.40	-1.10	-2.70	-2.70
	Max	2.00	1.80	1.30	2.00

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)

090177e18e74aa75\Final\Final On: 30-May-2018 05:31 (GMT)

**Table 14.3.4.1.2.2**  
**PF-06410293 Protocol B5381001**  
**Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set**  
**Parameter: Hemoglobin (g/dL)**

		<b>Adalimumab-Pfizer (N=69)</b>	<b>Adalimumab-US (N=71)</b>	<b>Adalimumab-EU (N=70)</b>	<b>Total (N=210)</b>
<b>Study Day</b>					
Day71	n	69	71	70	210
	Mean	0.29	0.23	0.24	0.25
	SD	0.734	0.616	0.675	0.673
	Median	0.30	0.30	0.30	0.30
	Min	-1.20	-1.30	-1.60	-1.60
	Max	2.50	1.90	1.90	2.50

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)

090177e18e74aa75\Final\Final On: 30-May-2018 05:31 (GMT)

**Table 14.3.4.1.2.2**  
**PF-06410293 Protocol B5381001**  
**Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set**  
**Parameter: Hematocrit (%)**

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
<b>Study Day</b>					
Baseline	n	69	71	70	210
	Mean	42.79	43.57	43.53	43.30
	SD	2.424	2.621	2.841	2.647
	Median	43.00	43.90	43.15	43.00
	Min	37.00	37.00	36.10	36.10
	Max	47.30	50.00	49.10	50.00
Day4	n	69	71	70	210
	Mean	1.61	1.03	0.93	1.19
	SD	2.222	1.634	1.797	1.913
	Median	1.40	1.00	1.00	1.00
	Min	-2.50	-3.00	-3.00	-3.00
	Max	7.80	4.10	5.00	7.80
Day8	n	69	71	70	210
	Mean	1.61	1.35	1.30	1.42
	SD	2.139	1.610	1.918	1.895
	Median	2.00	1.10	1.10	1.35
	Min	-3.00	-2.00	-4.20	-4.20
	Max	8.00	5.00	5.50	8.00

Baseline is defined as the most recent measurement prior to dosing.  
 If more than one test fall into the same window, then the one closer to the target day will be selected for the window.  
 If two tests have equal distance to the target day, then the later one will be used.  
 Study Day is based on time windows.  
 Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)

090177e18e74aa75\Final\Final On: 30-May-2018 05:31 (GMT)

**Table 14.3.4.1.2.2**  
**PF-06410293 Protocol B5381001**  
**Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set**  
**Parameter: Hematocrit (%)**

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Day15	n	68	71	69	208
	Mean	0.43	0.34	-0.13	0.21
	SD	1.924	2.168	1.913	2.012
	Median	0.25	0.40	0.00	0.00
	Min	-5.00	-5.60	-5.10	-5.60
	Max	4.00	4.00	4.00	4.00
Day29	n	67	70	70	207
	Mean	0.57	0.65	0.43	0.55
	SD	2.302	1.926	2.304	2.174
	Median	0.00	0.95	0.80	0.80
	Min	-4.80	-5.00	-6.00	-6.00
	Max	7.90	5.00	6.00	7.90
Day43	n	67	71	69	207
	Mean	1.17	0.64	0.28	0.69
	SD	2.443	2.164	2.467	2.376
	Median	1.00	1.00	0.00	0.90
	Min	-6.00	-5.60	-9.80	-9.80
	Max	7.00	7.00	5.00	7.00

Baseline is defined as the most recent measurement prior to dosing.  
 If more than one test fall into the same window, then the one closer to the target day will be selected for the window.  
 If two tests have equal distance to the target day, then the later one will be used.  
 Study Day is based on time windows.  
 Lab results in standard units have been used in the presentation.

090177e18e74aa75\Final\Final On: 30-May-2018 05:31 (GMT)

**Table 14.3.4.1.2.2**  
**PF-06410293 Protocol B5381001**  
**Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set**  
**Parameter: Hematocrit (%)**

		<b>Adalimumab-Pfizer (N=69)</b>	<b>Adalimumab-US (N=71)</b>	<b>Adalimumab-EU (N=70)</b>	<b>Total (N=210)</b>
<b>Study Day</b>					
Day71	n	69	71	70	210
	Mean	0.99	0.70	0.47	0.72
	SD	2.362	2.267	2.371	2.332
	Median	1.00	1.00	0.65	1.00
	Min	-3.70	-5.60	-6.60	-6.60
	Max	8.00	5.00	4.70	8.00

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)

090177e18e74aa75\Final\Final On: 30-May-2018 05:31 (GMT)

**Table 14.3.4.1.2.2**  
**PF-06410293 Protocol B5381001**  
**Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set**  
**Parameter: Erythrocytes (10<sup>6</sup>/mm<sup>3</sup>)**

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
<b>Study Day</b>					
Baseline	n	69	71	70	210
	Mean	4.91	4.99	5.04	4.98
	SD	0.343	0.405	0.402	0.386
	Median	4.89	4.99	5.02	4.98
	Min	4.17	4.11	4.14	4.11
	Max	5.69	5.96	6.09	6.09
Day4	n	69	71	70	210
	Mean	0.18	0.11	0.10	0.13
	SD	0.242	0.171	0.215	0.213
	Median	0.18	0.11	0.11	0.13
	Min	-0.24	-0.27	-0.37	-0.37
	Max	0.86	0.45	0.63	0.86
Day8	n	69	71	70	210
	Mean	0.17	0.14	0.13	0.14
	SD	0.231	0.160	0.222	0.206
	Median	0.18	0.13	0.13	0.15
	Min	-0.32	-0.22	-0.51	-0.51
	Max	0.87	0.55	0.68	0.87

Baseline is defined as the most recent measurement prior to dosing.  
 If more than one test fall into the same window, then the one closer to the target day will be selected for the window.  
 If two tests have equal distance to the target day, then the later one will be used.  
 Study Day is based on time windows.  
 Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)

090177e18e74aa75\Final\Final On: 30-May-2018 05:31 (GMT)



**Table 14.3.4.1.2.2**  
**PF-06410293 Protocol B5381001**  
**Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set**  
**Parameter: Erythrocytes (10<sup>6</sup>/mm<sup>3</sup>)**

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
<b>Study Day</b>					
Day15	n	68	71	69	208
	Mean	0.04	0.02	-0.03	0.01
	SD	0.201	0.219	0.206	0.210
	Median	0.03	0.01	-0.01	0.01
	Min	-0.55	-0.61	-0.64	-0.64
	Max	0.49	0.48	0.47	0.49
Day29	n	67	70	70	207
	Mean	0.06	0.05	0.02	0.04
	SD	0.234	0.187	0.248	0.224
	Median	0.06	0.05	0.04	0.05
	Min	-0.47	-0.48	-0.74	-0.74
	Max	0.86	0.44	0.64	0.86
Day43	n	67	71	69	207
	Mean	0.13	0.06	0.02	0.07
	SD	0.248	0.223	0.256	0.246
	Median	0.12	0.07	0.01	0.07
	Min	-0.70	-0.47	-1.13	-1.13
	Max	0.58	0.69	0.51	0.69

Baseline is defined as the most recent measurement prior to dosing.  
 If more than one test fall into the same window, then the one closer to the target day will be selected for the window.  
 If two tests have equal distance to the target day, then the later one will be used.  
 Study Day is based on time windows.  
 Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)

090177e18e74aa75\Final\Final On: 30-May-2018 05:31 (GMT)

**Table 14.3.4.1.2.2**  
**PF-06410293 Protocol B5381001**  
**Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set**  
**Parameter: Erythrocytes (10<sup>6</sup>/mm<sup>3</sup>)**

		<b>Adalimumab-Pfizer (N=69)</b>	<b>Adalimumab-US (N=71)</b>	<b>Adalimumab-EU (N=70)</b>	<b>Total (N=210)</b>
<b>Study Day</b>					
Day71	n	69	71	70	210
	Mean	0.13	0.09	0.07	0.10
	SD	0.251	0.225	0.276	0.251
	Median	0.13	0.09	0.08	0.09
	Min	-0.33	-0.50	-0.89	-0.89
	Max	0.87	0.54	0.64	0.87

090177e18e74aa75\Final\Final On: 30-May-2018 05:31 (GMT)

Baseline is defined as the most recent measurement prior to dosing.  
 If more than one test fall into the same window, then the one closer to the target day will be selected for the window.  
 If two tests have equal distance to the target day, then the later one will be used.  
 Study Day is based on time windows.  
 Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)

**Table 14.3.4.1.2.2**  
**PF-06410293 Protocol B5381001**  
**Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set**  
**Parameter: Ery. Mean Corpuscular Volume (10<sup>-15</sup>L)**

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
<b>Study Day</b>					
Baseline	n	69	71	70	210
	Mean	87.24	87.50	86.49	87.08
	SD	3.831	4.815	4.123	4.282
	Median	88.00	87.30	86.20	87.00
	Min	78.30	78.00	75.40	75.40
	Max	95.20	99.60	94.60	99.60
Day4	n	69	71	70	210
	Mean	0.06	0.22	0.10	0.13
	SD	1.114	1.214	1.138	1.153
	Median	0.00	0.00	0.00	0.00
	Min	-2.50	-1.80	-2.00	-2.50
	Max	4.00	4.40	3.30	4.40
Day8	n	69	71	70	210
	Mean	0.14	0.35	0.39	0.30
	SD	1.154	1.078	1.245	1.160
	Median	0.00	0.00	0.00	0.00
	Min	-3.50	-2.00	-2.00	-3.50
	Max	4.00	3.00	5.00	5.00

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)

090177e18e74aa75\Final\Final On: 30-May-2018 05:31 (GMT)

**Table 14.3.4.1.2.2**  
**PF-06410293 Protocol B5381001**  
**Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set**  
**Parameter: Ery. Mean Corpuscular Volume (10<sup>-15</sup>L)**

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
<b>Study Day</b>					
Day15	n	68	71	69	208
	Mean	0.24	0.39	0.34	0.32
	SD	1.247	1.122	1.416	1.262
	Median	0.00	0.20	0.20	0.10
	Min	-4.20	-1.80	-3.00	-4.20
	Max	3.00	4.00	4.00	4.00
Day29	n	67	70	70	207
	Mean	0.20	0.49	0.45	0.38
	SD	1.572	1.341	1.521	1.478
	Median	0.00	0.60	0.05	0.00
	Min	-3.80	-2.80	-3.00	-3.80
	Max	4.00	4.00	5.00	5.00
Day43	n	67	71	69	207
	Mean	0.03	0.28	0.19	0.17
	SD	1.948	1.657	1.704	1.766
	Median	0.00	0.00	0.00	0.00
	Min	-4.70	-3.00	-3.30	-4.70
	Max	4.00	4.00	5.00	5.00

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)

**Table 14.3.4.1.2.2**  
**PF-06410293 Protocol B5381001**  
**Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set**  
**Parameter: Ery. Mean Corpuscular Volume (10<sup>-15</sup>L)**

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
<b>Study Day</b>					
Day71	n	69	71	70	210
	Mean	-0.31	-0.13	-0.21	-0.22
	SD	2.273	2.214	2.040	2.169
	Median	0.00	0.00	0.00	0.00
	Min	-6.40	-3.90	-4.00	-6.40
	Max	5.00	5.00	5.00	5.00

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)

**Table 14.3.4.1.2.2**  
**PF-06410293 Protocol B5381001**  
**Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set**  
**Parameter: Ery. Mean Corpuscular Hemoglobin (pg/cell)**

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
<b>Study Day</b>					
Baseline	n	69	71	70	210
	Mean	29.86	30.12	29.75	29.91
	SD	1.677	2.020	1.809	1.840
	Median	30.00	30.00	30.00	30.00
	Min	25.90	25.50	24.30	24.30
	Max	33.10	35.00	32.50	35.00
Day4	n	69	71	70	210
	Mean	0.04	0.07	-0.07	0.01
	SD	0.618	0.577	0.512	0.571
	Median	0.00	0.00	0.00	0.00
	Min	-1.90	-1.00	-1.00	-1.90
	Max	1.20	1.50	1.00	1.50
Day8	n	69	71	70	210
	Mean	0.08	0.01	-0.09	-0.00
	SD	0.717	0.676	0.614	0.671
	Median	0.00	0.00	0.00	0.00
	Min	-2.50	-2.00	-1.70	-2.50
	Max	2.00	2.30	1.60	2.30

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)

**Table 14.3.4.1.2.2**  
**PF-06410293 Protocol B5381001**  
**Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set**  
**Parameter: Ery. Mean Corpuscular Hemoglobin (pg/cell)**

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
<b>Study Day</b>					
Day15	n	68	71	69	208
	Mean	-0.11	-0.01	-0.06	-0.06
	SD	0.618	0.674	0.660	0.650
	Median	0.00	0.00	0.00	0.00
	Min	-1.80	-2.00	-2.00	-2.00
	Max	1.00	1.40	1.00	1.40
Day29	n	67	70	70	207
	Mean	-0.01	-0.01	0.03	0.00
	SD	0.628	0.616	0.607	0.614
	Median	0.00	0.00	0.00	0.00
	Min	-1.70	-1.00	-1.80	-1.80
	Max	1.00	1.00	1.20	1.20
Day43	n	67	71	69	207
	Mean	-0.06	-0.12	-0.04	-0.08
	SD	0.746	0.654	0.677	0.690
	Median	0.00	0.00	0.00	0.00
	Min	-2.00	-2.00	-2.60	-2.60
	Max	1.00	1.00	1.50	1.50

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)

**Table 14.3.4.1.2.2**  
**PF-06410293 Protocol B5381001**  
**Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set**  
**Parameter: Ery. Mean Corpuscular Hemoglobin (pg/cell)**

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
<b>Study Day</b>					
Day71	n	69	71	70	210
	Mean	-0.16	-0.07	0.05	-0.06
	SD	0.708	0.714	0.837	0.757
	Median	0.00	0.00	0.00	0.00
	Min	-2.00	-2.00	-2.60	-2.60
	Max	1.30	1.40	3.40	3.40

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)



**Table 14.3.4.1.2.2**  
**PF-06410293 Protocol B5381001**  
**Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set**  
**Parameter: Ery. Mean Corpuscular HGB Concentration (g/dL)**

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
<b>Study Day</b>					
Baseline	n	69	71	70	210
	Mean	34.28	34.37	34.34	34.33
	SD	1.114	1.267	1.226	1.200
	Median	34.40	34.50	34.50	34.50
	Min	32.00	30.50	32.00	30.50
	Max	36.90	36.90	37.50	37.50
Day4	n	69	71	70	210
	Mean	-0.04	0.04	-0.11	-0.04
	SD	0.622	0.654	0.535	0.606
	Median	0.00	0.00	-0.10	0.00
	Min	-1.70	-1.40	-1.70	-1.70
	Max	1.20	2.00	1.10	2.00
Day8	n	69	71	70	210
	Mean	-0.06	-0.04	-0.20	-0.10
	SD	0.737	0.732	0.682	0.718
	Median	-0.10	0.00	-0.20	-0.10
	Min	-2.10	-2.50	-2.10	-2.50
	Max	1.70	1.70	1.60	1.70

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)

**Table 14.3.4.1.2.2**  
**PF-06410293 Protocol B5381001**  
**Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set**  
**Parameter: Ery. Mean Corpuscular HGB Concentration (g/dL)**

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
<b>Study Day</b>					
Day15	n	68	71	69	208
	Mean	-0.24	-0.15	-0.14	-0.17
	SD	0.679	0.768	0.785	0.744
	Median	-0.30	-0.10	-0.10	-0.20
	Min	-1.80	-1.90	-1.90	-1.90
	Max	1.30	2.00	1.70	2.00
Day29	n	67	70	70	207
	Mean	-0.15	-0.15	-0.11	-0.14
	SD	0.820	0.786	0.866	0.821
	Median	-0.10	-0.10	0.00	-0.10
	Min	-2.10	-1.90	-3.10	-3.10
	Max	1.40	1.40	1.80	1.80
Day43	n	67	71	69	207
	Mean	-0.13	-0.13	-0.07	-0.11
	SD	1.021	1.011	0.955	0.991
	Median	-0.10	-0.20	0.00	-0.10
	Min	-3.20	-3.30	-2.50	-3.30
	Max	1.80	1.90	2.20	2.20

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)

**Table 14.3.4.1.2.2**  
**PF-06410293 Protocol B5381001**  
**Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set**  
**Parameter: Ery. Mean Corpuscular HGB Concentration (g/dL)**

		<b>Adalimumab-Pfizer (N=69)</b>	<b>Adalimumab-US (N=71)</b>	<b>Adalimumab-EU (N=70)</b>	<b>Total (N=210)</b>
<b>Study Day</b>					
Day71	n	69	71	70	210
	Mean	-0.10	0.02	0.15	0.03
	SD	1.055	1.248	1.079	1.131
	Median	-0.10	0.00	0.15	0.00
	Min	-2.10	-2.10	-2.20	-2.20
	Max	2.30	2.50	3.30	3.30

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)

**Table 14.3.4.1.2.2**  
**PF-06410293 Protocol B5381001**  
**Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set**  
**Parameter: Mean Platelet Volume (fL)**

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
<b>Study Day</b>					
Baseline	n	69	71	70	210
	Mean	8.41	8.33	8.16	8.30
	SD	1.425	1.576	1.392	1.464
	Median	8.10	8.50	8.25	8.30
	Min	5.30	5.60	5.40	5.30
	Max	11.30	13.00	10.70	13.00
Day4	n	69	71	70	210
	Mean	0.30	0.23	0.22	0.25
	SD	0.900	0.876	0.859	0.875
	Median	0.20	0.20	0.05	0.10
	Min	-1.10	-1.90	-2.10	-2.10
	Max	3.10	2.80	2.40	3.10
Day8	n	69	71	70	210
	Mean	0.24	0.05	0.19	0.16
	SD	0.999	1.038	1.117	1.050
	Median	0.20	0.00	0.00	0.10
	Min	-1.80	-2.10	-2.00	-2.10
	Max	2.90	2.80	3.00	3.00

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)

090177e18e74aa75\Final\Final On: 30-May-2018 05:31 (GMT)

**Table 14.3.4.1.2.2**  
**PF-06410293 Protocol B5381001**  
**Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set**  
**Parameter: Mean Platelet Volume (fL)**

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
<b>Study Day</b>					
Day15	n	68	71	69	208
	Mean	0.36	0.18	0.12	0.22
	SD	0.971	1.009	1.099	1.028
	Median	0.20	0.00	0.00	0.00
	Min	-1.80	-2.30	-1.80	-2.30
	Max	2.90	2.70	2.70	2.90
Day29	n	67	70	70	207
	Mean	0.33	0.27	0.19	0.26
	SD	1.222	1.078	1.094	1.127
	Median	0.20	0.15	-0.10	0.00
	Min	-1.90	-2.40	-1.80	-2.40
	Max	3.00	2.40	3.10	3.10
Day43	n	67	71	69	207
	Mean	0.32	0.24	0.15	0.24
	SD	1.119	0.886	1.110	1.039
	Median	0.10	0.10	0.00	0.10
	Min	-1.90	-1.60	-2.50	-2.50
	Max	2.60	2.10	2.80	2.80

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)

**Table 14.3.4.1.2.2**  
**PF-06410293 Protocol B5381001**  
**Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set**  
**Parameter: Mean Platelet Volume (fL)**

		<b>Adalimumab-Pfizer (N=69)</b>	<b>Adalimumab-US (N=71)</b>	<b>Adalimumab-EU (N=70)</b>	<b>Total (N=210)</b>
<b>Study Day</b>					
Day71	n	69	71	70	210
	Mean	0.29	0.12	0.10	0.17
	SD	1.222	1.167	1.050	1.146
	Median	0.00	-0.10	-0.15	-0.10
	Min	-2.00	-1.80	-1.50	-2.00
	Max	3.30	3.40	2.80	3.40

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)

**Table 14.3.4.1.2.2**  
**PF-06410293 Protocol B5381001**  
**Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set**  
**Parameter: Platelets (10<sup>3</sup>/mm<sup>3</sup>)**

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
<b>Study Day</b>					
Baseline	n	69	71	70	210
	Mean	235.26	238.08	244.24	239.21
	SD	51.670	55.548	52.398	53.128
	Median	237.00	228.00	236.00	236.00
	Min	146.00	121.00	151.00	121.00
	Max	442.00	385.00	363.00	442.00
Day4	n	69	71	70	210
	Mean	-4.71	0.14	-2.90	-2.47
	SD	21.118	19.430	22.997	21.217
	Median	-6.00	0.00	-1.50	-2.00
	Min	-70.00	-48.00	-69.00	-70.00
	Max	43.00	51.00	56.00	56.00
Day8	n	69	71	70	210
	Mean	-4.49	-1.65	2.40	-1.23
	SD	27.051	23.326	27.365	25.991
	Median	-3.00	3.00	0.50	-0.50
	Min	-120.00	-65.00	-55.00	-120.00
	Max	52.00	56.00	79.00	79.00

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)

**Table 14.3.4.1.2.2**  
**PF-06410293 Protocol B5381001**  
**Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set**  
**Parameter: Platelets (10<sup>3</sup>/mm<sup>3</sup>)**

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
<b>Study Day</b>					
Day15	n	68	71	69	208
	Mean	-4.82	-7.96	-2.71	-5.19
	SD	26.363	30.950	26.680	28.061
	Median	-6.00	-11.00	-5.00	-5.50
	Min	-66.00	-86.00	-84.00	-86.00
	Max	62.00	82.00	53.00	82.00
Day29	n	67	70	70	207
	Mean	-8.07	-3.43	-6.54	-5.99
	SD	27.535	28.304	30.384	28.709
	Median	-7.00	-5.00	-6.00	-6.00
	Min	-75.00	-54.00	-140.00	-140.00
	Max	97.00	66.00	71.00	97.00
Day43	n	67	71	69	207
	Mean	2.19	2.31	0.04	1.52
	SD	27.012	26.884	30.115	27.926
	Median	-3.00	5.00	-2.00	2.00
	Min	-55.00	-61.00	-137.00	-137.00
	Max	94.00	64.00	100.00	100.00

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)



**Table 14.3.4.1.2.2**  
**PF-06410293 Protocol B5381001**  
**Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set**  
**Parameter: Platelets (10<sup>3</sup>/mm<sup>3</sup>)**

		<b>Adalimumab-Pfizer (N=69)</b>	<b>Adalimumab-US (N=71)</b>	<b>Adalimumab-EU (N=70)</b>	<b>Total (N=210)</b>
<b>Study Day</b>					
Day71	n	69	71	70	210
	Mean	-1.36	-3.07	1.76	-0.90
	SD	30.767	24.661	24.079	26.592
	Median	-5.00	1.00	2.50	1.00
	Min	-48.00	-57.00	-63.00	-63.00
	Max	123.00	63.00	64.00	123.00

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)

**Table 14.3.4.1.2.2**  
**PF-06410293 Protocol B5381001**  
**Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set**  
**Parameter: Leukocytes (10<sup>3</sup>/mm<sup>3</sup>)**

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
<b>Study Day</b>					
Baseline	n	69	71	70	210
	Mean	6.26	6.60	6.44	6.43
	SD	1.397	1.605	1.447	1.486
	Median	6.20	6.30	6.20	6.25
	Min	3.30	3.10	3.30	3.10
	Max	10.10	10.40	9.20	10.40
Day4	n	69	71	70	210
	Mean	-0.58	-0.67	-0.62	-0.62
	SD	1.096	1.296	1.146	1.178
	Median	-0.50	-0.60	-0.50	-0.50
	Min	-3.20	-5.30	-3.80	-5.30
	Max	1.50	1.90	2.70	2.70
Day8	n	69	71	70	210
	Mean	-0.52	-0.64	-0.57	-0.58
	SD	1.147	1.320	1.025	1.167
	Median	-0.30	-0.40	-0.45	-0.40
	Min	-2.90	-6.10	-3.20	-6.10
	Max	1.70	2.10	3.00	3.00

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)

090177e18e74aa75\Final\Final On: 30-May-2018 05:31 (GMT)

**Table 14.3.4.1.2.2**  
**PF-06410293 Protocol B5381001**  
**Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set**  
**Parameter: Leukocytes (10<sup>3</sup>/mm<sup>3</sup>)**

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
<b>Study Day</b>					
Day15	n	68	71	69	208
	Mean	-0.40	-0.53	-0.50	-0.48
	SD	1.124	1.309	1.355	1.263
	Median	-0.40	-0.40	-0.40	-0.40
	Min	-3.50	-4.70	-3.70	-4.70
	Max	2.60	2.00	4.70	4.70
Day29	n	67	70	70	207
	Mean	-0.20	-0.79	-0.49	-0.50
	SD	1.346	1.497	1.205	1.370
	Median	-0.30	-0.70	-0.55	-0.60
	Min	-2.90	-6.50	-3.50	-6.50
	Max	4.80	2.30	2.50	4.80
Day43	n	67	71	69	207
	Mean	-0.17	-0.56	-0.42	-0.39
	SD	1.271	1.356	1.218	1.287
	Median	-0.20	-0.40	-0.40	-0.40
	Min	-3.00	-5.70	-3.90	-5.70
	Max	3.10	2.70	2.00	3.10

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)

**Table 14.3.4.1.2.2**  
**PF-06410293 Protocol B5381001**  
**Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set**  
**Parameter: Leukocytes (10<sup>3</sup>/mm<sup>3</sup>)**

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
<b>Study Day</b>					
Day71	n	69	71	70	210
	Mean	-0.13	-0.45	-0.24	-0.27
	SD	1.465	1.359	1.077	1.310
	Median	0.00	-0.30	-0.20	-0.20
	Min	-3.30	-5.90	-2.80	-5.90
	Max	5.60	2.40	2.30	5.60

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)

**Table 14.3.4.1.2.2**  
**PF-06410293 Protocol B5381001**  
**Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set**  
**Parameter: Lymphocytes (10<sup>3</sup>/mm<sup>3</sup>)**

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
<b>Study Day</b>					
Baseline	n	69	71	70	210
	Mean	1.93	1.97	2.00	1.97
	SD	0.520	0.547	0.429	0.500
	Median	1.87	1.93	2.00	1.94
	Min	0.75	0.80	1.00	0.75
	Max	3.88	3.30	3.34	3.88
Day4	n	69	71	70	210
	Mean	0.24	0.29	0.21	0.25
	SD	0.446	0.406	0.384	0.412
	Median	0.15	0.30	0.20	0.20
	Min	-0.54	-0.90	-0.52	-0.90
	Max	1.20	1.35	1.24	1.35
Day8	n	69	71	70	210
	Mean	0.21	0.21	0.23	0.22
	SD	0.404	0.433	0.397	0.410
	Median	0.20	0.21	0.20	0.20
	Min	-0.59	-0.97	-0.55	-0.97
	Max	1.40	1.20	1.42	1.42

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)

**Table 14.3.4.1.2.2**  
**PF-06410293 Protocol B5381001**  
**Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set**  
**Parameter: Lymphocytes (10<sup>3</sup>/mm<sup>3</sup>)**

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
<b>Study Day</b>					
Day15	n	68	71	69	208
	Mean	0.22	0.16	0.10	0.16
	SD	0.432	0.475	0.441	0.450
	Median	0.14	0.12	0.10	0.11
	Min	-0.68	-1.10	-1.20	-1.20
	Max	1.20	1.37	0.96	1.37
Day29	n	67	70	70	207
	Mean	0.15	0.05	0.05	0.08
	SD	0.491	0.443	0.379	0.440
	Median	0.11	0.00	0.04	0.04
	Min	-0.90	-0.99	-0.62	-0.99
	Max	1.53	1.80	0.90	1.80
Day43	n	67	71	69	207
	Mean	0.14	-0.01	0.00	0.04
	SD	0.379	0.376	0.375	0.381
	Median	0.19	-0.01	-0.04	0.00
	Min	-0.57	-1.05	-0.96	-1.05
	Max	1.21	0.85	0.90	1.21

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)

**Table 14.3.4.1.2.2**  
**PF-06410293 Protocol B5381001**  
**Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set**  
**Parameter: Lymphocytes ( $10^3/\text{mm}^3$ )**

		<b>Adalimumab-Pfizer (N=69)</b>	<b>Adalimumab-US (N=71)</b>	<b>Adalimumab-EU (N=70)</b>	<b>Total (N=210)</b>
<b>Study Day</b>					
Day71	n	69	71	70	210
	Mean	0.05	-0.07	-0.08	-0.03
	SD	0.463	0.419	0.349	0.415
	Median	0.00	-0.10	-0.09	-0.01
	Min	-1.07	-1.04	-1.20	-1.20
	Max	1.52	1.40	0.62	1.52

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)

**Table 14.3.4.1.2.2**  
**PF-06410293 Protocol B5381001**  
**Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set**  
**Parameter: Lymphocytes/Leukocytes (%)**

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
<b>Study Day</b>					
Baseline	n	69	71	70	210
	Mean	31.54	30.73	31.92	31.40
	SD	7.827	8.416	7.583	7.930
	Median	31.10	30.10	31.30	30.80
	Min	13.10	14.10	17.40	13.10
	Max	51.80	52.80	47.50	52.80
Day4	n	69	71	70	210
	Mean	6.97	7.89	6.96	7.28
	SD	6.312	6.883	6.987	6.718
	Median	6.30	6.30	6.25	6.30
	Min	-4.60	-8.40	-9.60	-9.60
	Max	20.80	27.40	36.30	36.30
Day8	n	69	71	70	210
	Mean	5.90	6.12	6.84	6.29
	SD	6.093	7.715	6.367	6.750
	Median	5.90	5.60	5.95	5.85
	Min	-10.40	-13.90	-5.90	-13.90
	Max	20.10	22.50	27.40	27.40

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)



**Table 14.3.4.1.2.2**  
**PF-06410293 Protocol B5381001**  
**Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set**  
**Parameter: Lymphocytes/Leukocytes (%)**

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
<b>Study Day</b>					
Day15	n	68	71	69	208
	Mean	5.82	4.83	4.78	5.14
	SD	6.359	7.014	7.971	7.129
	Median	5.15	3.90	5.60	4.90
	Min	-7.80	-12.60	-28.10	-28.10
	Max	20.10	19.80	23.70	23.70
Day29	n	67	70	70	207
	Mean	3.67	4.22	3.87	3.92
	SD	7.352	7.062	7.015	7.110
	Median	4.00	3.60	4.80	4.10
	Min	-20.70	-13.40	-20.70	-20.70
	Max	24.70	24.00	25.40	25.40
Day43	n	67	71	69	207
	Mean	3.31	2.28	2.58	2.71
	SD	6.586	7.454	6.312	6.791
	Median	1.50	2.60	2.00	2.00
	Min	-8.40	-20.20	-14.30	-20.20
	Max	19.40	18.80	22.00	22.00

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)

**Table 14.3.4.1.2.2**  
**PF-06410293 Protocol B5381001**  
**Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set**  
**Parameter: Lymphocytes/Leukocytes (%)**

		<b>Adalimumab-Pfizer (N=69)</b>	<b>Adalimumab-US (N=71)</b>	<b>Adalimumab-EU (N=70)</b>	<b>Total (N=210)</b>
<b>Study Day</b>					
Day71	n	69	71	70	210
	Mean	1.45	0.54	0.37	0.78
	SD	7.306	6.869	5.968	6.720
	Median	0.30	0.40	0.15	0.30
	Min	-17.90	-16.90	-13.50	-17.90
	Max	19.70	20.60	22.40	22.40

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)

**Table 14.3.4.1.2.2**  
**PF-06410293 Protocol B5381001**  
**Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set**  
**Parameter: Neutrophils ( $10^3/\text{mm}^3$ )**

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
<b>Study Day</b>					
Baseline	n	69	71	70	210
	Mean	3.62	3.84	3.72	3.73
	SD	1.109	1.390	1.280	1.263
	Median	3.50	3.73	3.51	3.55
	Min	1.70	1.60	1.70	1.60
	Max	6.70	7.37	7.00	7.37
Day4	n	69	71	70	210
	Mean	-0.82	-0.92	-0.85	-0.86
	SD	0.891	1.181	1.100	1.061
	Median	-0.75	-0.61	-0.68	-0.70
	Min	-3.10	-5.33	-4.16	-5.33
	Max	0.80	1.55	2.00	2.00
Day8	n	69	71	70	210
	Mean	-0.71	-0.79	-0.81	-0.77
	SD	0.962	1.246	0.970	1.065
	Median	-0.70	-0.50	-0.67	-0.60
	Min	-3.40	-5.61	-3.67	-5.61
	Max	1.70	1.40	2.13	2.13

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)

**Table 14.3.4.1.2.2**  
**PF-06410293 Protocol B5381001**  
**Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set**  
**Parameter: Neutrophils ( $10^3/\text{mm}^3$ )**

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
<b>Study Day</b>					
Day15	n	68	71	69	208
	Mean	-0.68	-0.69	-0.65	-0.67
	SD	0.891	1.168	1.275	1.119
	Median	-0.62	-0.50	-0.61	-0.60
	Min	-2.43	-4.87	-3.96	-4.87
	Max	2.04	1.75	3.40	3.40
Day29	n	67	70	70	207
	Mean	-0.44	-0.81	-0.60	-0.62
	SD	1.062	1.330	1.104	1.177
	Median	-0.50	-0.60	-0.50	-0.50
	Min	-2.66	-5.49	-3.27	-5.49
	Max	3.50	1.77	2.82	3.50
Day43	n	67	71	69	207
	Mean	-0.37	-0.55	-0.48	-0.47
	SD	1.150	1.256	1.072	1.159
	Median	-0.40	-0.49	-0.40	-0.40
	Min	-3.50	-5.15	-3.40	-5.15
	Max	3.00	2.87	1.90	3.00

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)

**Table 14.3.4.1.2.2**  
**PF-06410293 Protocol B5381001**  
**Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set**  
**Parameter: Neutrophils ( $10^3/\text{mm}^3$ )**

		<b>Adalimumab-Pfizer (N=69)</b>	<b>Adalimumab-US (N=71)</b>	<b>Adalimumab-EU (N=70)</b>	<b>Total (N=210)</b>
<b>Study Day</b>					
Day71	n	69	71	70	210
	Mean	-0.21	-0.39	-0.24	-0.28
	SD	1.222	1.199	0.960	1.130
	Median	-0.11	-0.17	-0.20	-0.18
	Min	-2.70	-5.29	-2.85	-5.29
	Max	4.60	1.70	1.83	4.60

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)

**Table 14.3.4.1.2.2**  
**PF-06410293 Protocol B5381001**  
**Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set**  
**Parameter: Neutrophils/Leukocytes (%)**

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
<b>Study Day</b>					
Baseline	n	69	71	70	210
	Mean	57.03	57.02	56.38	56.81
	SD	8.495	9.128	8.768	8.767
	Median	56.00	55.80	56.30	56.15
	Min	35.70	35.80	32.80	32.80
	Max	78.10	79.20	74.10	79.20
Day4	n	69	71	70	210
	Mean	-8.08	-8.49	-8.02	-8.20
	SD	7.405	7.759	8.499	7.868
	Median	-7.50	-6.70	-7.35	-7.30
	Min	-26.30	-32.00	-41.80	-41.80
	Max	4.50	8.80	10.60	10.60
Day8	n	69	71	70	210
	Mean	-6.64	-6.85	-7.61	-7.03
	SD	7.049	8.448	7.534	7.680
	Median	-6.50	-6.20	-6.80	-6.55
	Min	-22.40	-30.30	-28.90	-30.30
	Max	11.70	9.50	6.90	11.70

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)

090177e18e74aa75\Final\Final On: 30-May-2018 05:31 (GMT)

**Table 14.3.4.1.2.2**  
**PF-06410293 Protocol B5381001**  
**Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set**  
**Parameter: Neutrophils/Leukocytes (%)**

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
<b>Study Day</b>					
Day15	n	68	71	69	208
	Mean	-7.45	-5.93	-6.14	-6.50
	SD	7.501	8.038	9.331	8.314
	Median	-7.05	-4.80	-7.20	-6.15
	Min	-25.20	-27.70	-29.40	-29.40
	Max	8.50	12.20	35.30	35.30
Day29	n	67	70	70	207
	Mean	-5.60	-5.32	-5.60	-5.50
	SD	8.145	8.591	7.953	8.197
	Median	-5.70	-4.60	-6.40	-5.40
	Min	-25.70	-36.50	-31.00	-36.50
	Max	16.70	13.30	22.90	22.90
Day43	n	67	71	69	207
	Mean	-4.73	-3.24	-3.94	-3.95
	SD	8.177	8.099	7.660	7.966
	Median	-2.90	-3.20	-3.20	-3.20
	Min	-23.60	-21.80	-28.70	-28.70
	Max	11.20	21.80	13.60	21.80

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)

**Table 14.3.4.1.2.2**  
**PF-06410293 Protocol B5381001**  
**Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set**  
**Parameter: Neutrophils/Leukocytes (%)**

		<b>Adalimumab-Pfizer (N=69)</b>	<b>Adalimumab-US (N=71)</b>	<b>Adalimumab-EU (N=70)</b>	<b>Total (N=210)</b>
<b>Study Day</b>					
Day71	n	69	71	70	210
	Mean	-2.09	-1.42	-1.54	-1.68
	SD	8.492	7.583	7.359	7.790
	Median	0.20	-1.10	-1.00	-0.20
	Min	-19.40	-23.20	-32.10	-32.10
	Max	15.70	18.20	14.10	18.20

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)



**Table 14.3.4.1.2.2**  
**PF-06410293 Protocol B5381001**  
**Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set**  
**Parameter: Basophils (10<sup>3</sup>/mm<sup>3</sup>)**

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
<b>Study Day</b>					
Baseline	n	69	71	70	210
	Mean	0.06	0.06	0.06	0.06
	SD	0.040	0.039	0.040	0.039
	Median	0.04	0.04	0.05	0.05
	Min	0.00	0.00	0.00	0.00
	Max	0.20	0.20	0.20	0.20
Day4	n	69	71	70	210
	Mean	0.00	-0.00	0.01	0.00
	SD	0.034	0.029	0.032	0.032
	Median	0.00	0.00	0.00	0.00
	Min	-0.10	-0.10	-0.10	-0.10
	Max	0.10	0.10	0.10	0.10
Day8	n	69	71	70	210
	Mean	0.00	0.00	0.01	0.00
	SD	0.030	0.033	0.030	0.031
	Median	0.00	0.00	0.00	0.00
	Min	-0.10	-0.10	-0.10	-0.10
	Max	0.10	0.10	0.10	0.10

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)

**Table 14.3.4.1.2.2**  
**PF-06410293 Protocol B5381001**  
**Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set**  
**Parameter: Basophils (10<sup>3</sup>/mm<sup>3</sup>)**

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
<b>Study Day</b>					
Day15	n	68	71	69	208
	Mean	0.00	0.00	0.01	0.00
	SD	0.022	0.031	0.024	0.026
	Median	0.00	0.00	0.00	0.00
	Min	-0.10	-0.10	-0.03	-0.10
	Max	0.05	0.10	0.10	0.10
Day29	n	67	70	70	207
	Mean	0.00	0.00	-0.00	0.00
	SD	0.024	0.027	0.034	0.029
	Median	0.00	0.00	0.00	0.00
	Min	-0.10	-0.10	-0.10	-0.10
	Max	0.10	0.10	0.10	0.10
Day43	n	67	71	69	207
	Mean	0.01	0.00	0.00	0.01
	SD	0.025	0.026	0.032	0.028
	Median	0.00	0.00	0.00	0.00
	Min	-0.02	-0.10	-0.10	-0.10
	Max	0.10	0.10	0.10	0.10

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)

**Table 14.3.4.1.2.2**  
**PF-06410293 Protocol B5381001**  
**Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set**  
**Parameter: Basophils (10<sup>3</sup>/mm<sup>3</sup>)**

		<b>Adalimumab-Pfizer (N=69)</b>	<b>Adalimumab-US (N=71)</b>	<b>Adalimumab-EU (N=70)</b>	<b>Total (N=210)</b>
<b>Study Day</b>					
Day71	n	69	71	70	210
	Mean	-0.00	-0.00	0.01	0.00
	SD	0.033	0.020	0.031	0.029
	Median	0.00	0.00	0.00	0.00
	Min	-0.10	-0.10	-0.10	-0.10
	Max	0.10	0.04	0.10	0.10

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)

**Table 14.3.4.1.2.2**  
**PF-06410293 Protocol B5381001**  
**Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set**  
**Parameter: Basophils/Leukocytes (%)**

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
<b>Study Day</b>					
Baseline	n	69	71	70	210
	Mean	0.87	0.85	0.86	0.86
	SD	0.534	0.505	0.557	0.530
	Median	0.70	0.70	0.80	0.70
	Min	0.20	0.20	0.10	0.10
	Max	2.60	2.10	2.70	2.70
Day4	n	69	71	70	210
	Mean	0.11	0.09	0.09	0.10
	SD	0.337	0.282	0.306	0.308
	Median	0.10	0.10	0.10	0.10
	Min	-0.80	-0.70	-0.70	-0.80
	Max	1.30	0.70	0.80	1.30
Day8	n	69	71	70	210
	Mean	0.06	0.15	0.13	0.11
	SD	0.307	0.440	0.362	0.374
	Median	0.10	0.10	0.20	0.10
	Min	-1.10	-0.80	-1.00	-1.10
	Max	0.80	2.70	1.40	2.70

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)

**Table 14.3.4.1.2.2**  
**PF-06410293 Protocol B5381001**  
**Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set**  
**Parameter: Basophils/Leukocytes (%)**

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
<b>Study Day</b>					
Day15	n	68	71	69	208
	Mean	0.12	0.15	0.12	0.13
	SD	0.310	0.341	0.327	0.326
	Median	0.10	0.20	0.10	0.10
	Min	-0.60	-0.80	-0.80	-0.80
	Max	1.10	1.20	1.20	1.20
Day29	n	67	70	70	207
	Mean	0.09	0.12	0.07	0.09
	SD	0.310	0.367	0.315	0.331
	Median	0.10	0.10	0.05	0.10
	Min	-0.80	-0.80	-0.80	-0.80
	Max	1.00	1.00	0.80	1.00
Day43	n	67	71	69	207
	Mean	0.16	0.16	0.10	0.14
	SD	0.362	0.400	0.355	0.372
	Median	0.10	0.10	0.00	0.10
	Min	-0.60	-0.70	-0.70	-0.70
	Max	2.10	1.30	1.20	2.10

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)

**Table 14.3.4.1.2.2**  
**PF-06410293 Protocol B5381001**  
**Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set**  
**Parameter: Basophils/Leukocytes (%)**

		<b>Adalimumab-Pfizer (N=69)</b>	<b>Adalimumab-US (N=71)</b>	<b>Adalimumab-EU (N=70)</b>	<b>Total (N=210)</b>
<b>Study Day</b>					
Day71	n	69	71	70	210
	Mean	0.01	0.06	0.08	0.05
	SD	0.319	0.238	0.317	0.293
	Median	0.00	0.10	0.10	0.10
	Min	-1.10	-0.60	-1.00	-1.10
	Max	1.10	0.60	0.90	1.10

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)

**Table 14.3.4.1.2.2**  
**PF-06410293 Protocol B5381001**  
**Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set**  
**Parameter: Eosinophils (10<sup>3</sup>/mm<sup>3</sup>)**

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
<b>Study Day</b>					
Baseline	n	69	71	70	210
	Mean	0.15	0.18	0.18	0.17
	SD	0.117	0.129	0.143	0.130
	Median	0.11	0.15	0.15	0.14
	Min	0.00	0.00	0.00	0.00
	Max	0.60	0.60	0.73	0.73
Day4	n	69	71	70	210
	Mean	0.03	0.03	0.01	0.02
	SD	0.081	0.091	0.081	0.085
	Median	0.01	0.00	0.00	0.00
	Min	-0.20	-0.30	-0.40	-0.40
	Max	0.42	0.30	0.20	0.42
Day8	n	69	71	70	210
	Mean	0.01	-0.01	-0.00	0.00
	SD	0.079	0.080	0.081	0.080
	Median	0.00	0.00	0.00	0.00
	Min	-0.30	-0.30	-0.30	-0.30
	Max	0.26	0.20	0.14	0.26

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)

**Table 14.3.4.1.2.2**  
**PF-06410293 Protocol B5381001**  
**Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set**  
**Parameter: Eosinophils ( $10^3/\text{mm}^3$ )**

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
<b>Study Day</b>					
Day15	n	68	71	69	208
	Mean	0.04	0.02	0.01	0.02
	SD	0.093	0.101	0.093	0.096
	Median	0.02	0.00	0.00	0.00
	Min	-0.40	-0.30	-0.34	-0.40
	Max	0.25	0.29	0.34	0.34
Day29	n	67	70	70	207
	Mean	0.04	-0.00	0.02	0.02
	SD	0.089	0.093	0.107	0.098
	Median	0.02	0.00	0.01	0.00
	Min	-0.30	-0.40	-0.46	-0.46
	Max	0.24	0.30	0.30	0.30
Day43	n	67	71	69	207
	Mean	0.03	0.01	0.01	0.02
	SD	0.106	0.123	0.113	0.114
	Median	0.01	0.00	0.00	0.00
	Min	-0.30	-0.30	-0.43	-0.43
	Max	0.41	0.70	0.50	0.70

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)



**Table 14.3.4.1.2.2**  
**PF-06410293 Protocol B5381001**  
**Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set**  
**Parameter: Eosinophils ( $10^3/\text{mm}^3$ )**

		<b>Adalimumab-Pfizer (N=69)</b>	<b>Adalimumab-US (N=71)</b>	<b>Adalimumab-EU (N=70)</b>	<b>Total (N=210)</b>
<b>Study Day</b>					
Day71	n	69	71	70	210
	Mean	0.02	0.02	0.01	0.02
	SD	0.086	0.092	0.134	0.106
	Median	0.01	0.00	0.00	0.00
	Min	-0.30	-0.20	-0.62	-0.62
	Max	0.20	0.40	0.30	0.40

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)

**Table 14.3.4.1.2.2**  
**PF-06410293 Protocol B5381001**  
**Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set**  
**Parameter: Eosinophils/Leukocytes (%)**

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
<b>Study Day</b>					
Baseline	n	69	71	70	210
	Mean	2.51	2.76	2.85	2.71
	SD	1.641	2.064	2.131	1.955
	Median	2.20	2.20	2.35	2.20
	Min	0.50	0.30	0.50	0.30
	Max	7.70	11.40	11.50	11.50
Day4	n	69	71	70	210
	Mean	0.65	0.68	0.55	0.63
	SD	1.092	1.189	1.389	1.226
	Median	0.50	0.60	0.55	0.55
	Min	-2.50	-2.80	-5.70	-5.70
	Max	5.30	4.10	4.00	5.30
Day8	n	69	71	70	210
	Mean	0.36	0.25	0.23	0.28
	SD	1.152	1.094	1.202	1.146
	Median	0.30	0.20	0.20	0.20
	Min	-3.90	-2.50	-4.00	-4.00
	Max	4.00	3.50	3.50	4.00

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)

**Table 14.3.4.1.2.2**  
**PF-06410293 Protocol B5381001**  
**Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set**  
**Parameter: Eosinophils/Leukocytes (%)**

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
<b>Study Day</b>					
Day15	n	68	71	69	208
	Mean	0.85	0.57	0.37	0.59
	SD	1.451	1.445	1.616	1.511
	Median	0.50	0.40	0.30	0.40
	Min	-3.80	-2.10	-7.20	-7.20
	Max	5.20	5.40	5.50	5.50
Day29	n	67	70	70	207
	Mean	0.69	0.42	0.67	0.59
	SD	1.344	1.290	1.576	1.408
	Median	0.60	0.50	0.40	0.50
	Min	-2.80	-4.70	-3.80	-4.70
	Max	4.50	4.70	6.60	6.60
Day43	n	67	71	69	207
	Mean	0.57	0.41	0.30	0.43
	SD	1.645	1.589	1.656	1.626
	Median	0.50	0.40	0.20	0.30
	Min	-3.50	-5.10	-4.30	-5.10
	Max	7.70	8.70	6.00	8.70

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)

**Table 14.3.4.1.2.2**  
**PF-06410293 Protocol B5381001**  
**Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set**  
**Parameter: Eosinophils/Leukocytes (%)**

		<b>Adalimumab-Pfizer (N=69)</b>	<b>Adalimumab-US (N=71)</b>	<b>Adalimumab-EU (N=70)</b>	<b>Total (N=210)</b>
<b>Study Day</b>					
Day71	n	69	71	70	210
	Mean	0.32	0.51	0.31	0.38
	SD	1.350	1.287	1.899	1.532
	Median	0.30	0.30	0.45	0.30
	Min	-3.60	-3.50	-6.40	-6.40
	Max	4.00	4.60	4.60	4.60

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)

090177e18e74aa75\Final\Final On: 30-May-2018 05:31 (GMT)

**Table 14.3.4.1.2.2**  
**PF-06410293 Protocol B5381001**  
**Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set**  
**Parameter: Monocytes (10<sup>3</sup>/mm<sup>3</sup>)**

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
<b>Study Day</b>					
Baseline	n	69	71	70	210
	Mean	0.42	0.47	0.45	0.45
	SD	0.118	0.157	0.157	0.146
	Median	0.40	0.44	0.41	0.42
	Min	0.20	0.20	0.20	0.20
	Max	0.70	1.00	1.10	1.10
Day4	n	69	71	70	210
	Mean	-0.03	-0.06	-0.04	-0.04
	SD	0.105	0.122	0.133	0.121
	Median	-0.01	-0.06	-0.01	-0.02
	Min	-0.40	-0.45	-0.60	-0.60
	Max	0.20	0.30	0.30	0.30
Day8	n	69	71	70	210
	Mean	-0.03	-0.03	-0.04	-0.03
	SD	0.113	0.136	0.124	0.124
	Median	-0.01	-0.04	-0.02	-0.02
	Min	-0.30	-0.40	-0.60	-0.60
	Max	0.43	0.52	0.20	0.52

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)

**Table 14.3.4.1.2.2**  
**PF-06410293 Protocol B5381001**  
**Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set**  
**Parameter: Monocytes (10<sup>3</sup>/mm<sup>3</sup>)**

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
<b>Study Day</b>					
Day15	n	68	71	69	208
	Mean	-0.00	-0.02	-0.01	-0.01
	SD	0.124	0.118	0.141	0.128
	Median	0.00	0.00	0.00	0.00
	Min	-0.30	-0.33	-0.50	-0.50
	Max	0.39	0.30	0.31	0.39
Day29	n	67	70	70	207
	Mean	0.04	-0.03	0.00	0.00
	SD	0.135	0.128	0.145	0.138
	Median	0.00	-0.04	0.00	0.00
	Min	-0.22	-0.39	-0.50	-0.50
	Max	0.60	0.30	0.50	0.60
Day43	n	67	71	69	207
	Mean	0.02	-0.02	0.01	0.00
	SD	0.098	0.138	0.140	0.128
	Median	0.00	-0.02	0.00	0.00
	Min	-0.22	-0.30	-0.40	-0.40
	Max	0.21	0.54	0.50	0.54

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)

090177e18e74aa75\Final\Final On: 30-May-2018 05:31 (GMT)

**Table 14.3.4.1.2.2**  
**PF-06410293 Protocol B5381001**  
**Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set**  
**Parameter: Monocytes (10<sup>3</sup>/mm<sup>3</sup>)**

		<b>Adalimumab-Pfizer (N=69)</b>	<b>Adalimumab-US (N=71)</b>	<b>Adalimumab-EU (N=70)</b>	<b>Total (N=210)</b>
<b>Study Day</b>					
Day71	n	69	71	70	210
	Mean	-0.00	-0.00	0.01	0.00
	SD	0.114	0.134	0.127	0.125
	Median	0.00	0.00	0.00	0.00
	Min	-0.22	-0.35	-0.40	-0.40
	Max	0.32	0.40	0.30	0.40

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)

**Table 14.3.4.1.2.2**  
**PF-06410293 Protocol B5381001**  
**Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set**  
**Parameter: Monocytes/Leukocytes (%)**

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
<b>Study Day</b>					
Baseline	n	69	71	70	210
	Mean	6.88	7.34	7.03	7.08
	SD	1.545	2.159	1.861	1.876
	Median	6.70	7.20	6.55	6.75
	Min	3.90	3.50	3.60	3.50
	Max	10.90	14.30	11.90	14.30
Day4	n	69	71	70	210
	Mean	0.18	-0.27	0.09	-0.00
	SD	1.416	1.600	1.433	1.492
	Median	0.20	-0.10	0.20	0.20
	Min	-2.90	-4.40	-3.40	-4.40
	Max	4.90	3.20	3.60	4.90
Day8	n	69	71	70	210
	Mean	0.13	0.27	0.06	0.15
	SD	1.495	2.320	1.457	1.800
	Median	0.10	0.00	-0.05	0.00
	Min	-2.40	-4.90	-4.00	-4.90
	Max	7.10	9.80	3.20	9.80

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)



**Table 14.3.4.1.2.2**  
**PF-06410293 Protocol B5381001**  
**Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set**  
**Parameter: Monocytes/Leukocytes (%)**

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
<b>Study Day</b>					
Day15	n	68	71	69	208
	Mean	0.39	0.25	0.50	0.38
	SD	1.372	1.514	1.636	1.508
	Median	0.30	0.30	0.20	0.30
	Min	-2.30	-2.90	-2.00	-2.90
	Max	4.70	3.60	8.40	8.40
Day29	n	67	70	70	207
	Mean	0.79	0.36	0.57	0.57
	SD	1.672	1.788	1.541	1.672
	Median	0.60	0.15	0.45	0.40
	Min	-2.50	-3.30	-3.20	-3.30
	Max	5.50	7.70	5.50	7.70
Day43	n	67	71	69	207
	Mean	0.53	0.29	0.70	0.50
	SD	1.450	1.637	1.550	1.551
	Median	0.40	0.10	0.60	0.40
	Min	-3.20	-3.60	-2.70	-3.60
	Max	4.40	7.40	7.20	7.40

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)

**Table 14.3.4.1.2.2**  
**PF-06410293 Protocol B5381001**  
**Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set**  
**Parameter: Monocytes/Leukocytes (%)**

		<b>Adalimumab-Pfizer (N=69)</b>	<b>Adalimumab-US (N=71)</b>	<b>Adalimumab-EU (N=70)</b>	<b>Total (N=210)</b>
<b>Study Day</b>					
Day71	n	69	71	70	210
	Mean	0.12	0.36	0.53	0.34
	SD	1.338	1.717	1.755	1.617
	Median	0.10	0.40	0.50	0.40
	Min	-3.30	-5.70	-2.80	-5.70
	Max	3.10	3.60	6.30	6.30

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)

**Table 14.3.4.1.2.2**  
**PF-06410293 Protocol B5381001**  
**Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set**  
**Parameter: Bilirubin (mg/dL)**

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
<b>Study Day</b>					
Baseline	n	69	71	70	210
	Mean	0.71	0.69	0.65	0.69
	SD	0.342	0.310	0.282	0.311
	Median	0.60	0.70	0.60	0.60
	Min	0.20	0.20	0.30	0.20
	Max	1.80	2.00	1.70	2.00
Day4	n	69	71	70	210
	Mean	0.01	-0.01	-0.03	-0.01
	SD	0.259	0.277	0.224	0.254
	Median	0.00	0.00	0.00	0.00
	Min	-1.10	-0.80	-0.70	-1.10
	Max	0.50	0.70	0.60	0.70
Day8	n	69	71	70	210
	Mean	0.05	0.01	-0.03	0.01
	SD	0.251	0.296	0.215	0.257
	Median	0.10	0.00	0.00	0.00
	Min	-1.00	-1.00	-0.60	-1.00
	Max	0.60	0.80	0.50	0.80

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)

090177e18e74aa75\Final\Final On: 30-May-2018 05:31 (GMT)

**Table 14.3.4.1.2.2**  
**PF-06410293 Protocol B5381001**  
**Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set**  
**Parameter: Bilirubin (mg/dL)**

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
<b>Study Day</b>					
Day15	n	68	71	69	208
	Mean	-0.03	-0.04	-0.07	-0.04
	SD	0.331	0.320	0.262	0.305
	Median	0.00	0.00	-0.10	0.00
	Min	-1.30	-0.80	-0.70	-1.30
	Max	0.70	1.60	0.90	1.60
Day29	n	67	70	70	207
	Mean	-0.02	0.01	-0.03	-0.01
	SD	0.351	0.300	0.241	0.299
	Median	0.00	0.00	0.00	0.00
	Min	-1.20	-0.90	-0.70	-1.20
	Max	1.30	0.70	0.50	1.30
Day43	n	67	71	69	207
	Mean	-0.00	-0.03	-0.01	-0.02
	SD	0.337	0.286	0.210	0.281
	Median	0.00	0.00	0.00	0.00
	Min	-1.30	-0.80	-0.70	-1.30
	Max	1.10	0.50	0.60	1.10

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)

**Table 14.3.4.1.2.2**  
**PF-06410293 Protocol B5381001**  
**Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set**  
**Parameter: Bilirubin (mg/dL)**

		<b>Adalimumab-Pfizer (N=69)</b>	<b>Adalimumab-US (N=71)</b>	<b>Adalimumab-EU (N=70)</b>	<b>Total (N=210)</b>
<b>Study Day</b>					
Day71	n	69	71	70	210
	Mean	-0.09	-0.04	-0.06	-0.06
	SD	0.334	0.281	0.267	0.294
	Median	-0.10	0.00	-0.05	-0.05
	Min	-1.40	-1.00	-0.70	-1.40
	Max	0.70	0.70	0.70	0.70

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)

**Table 14.3.4.1.2.2**  
**PF-06410293 Protocol B5381001**  
**Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set**  
**Parameter: Aspartate Aminotransferase (U/L)**

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
<b>Study Day</b>					
Baseline	n	69	71	70	210
	Mean	23.17	24.66	24.41	24.09
	SD	6.338	7.376	7.544	7.107
	Median	22.00	23.00	24.00	23.00
	Min	13.00	13.00	13.00	13.00
	Max	44.00	48.00	57.00	57.00
Day4	n	69	71	70	210
	Mean	-3.36	-4.13	-3.41	-3.64
	SD	4.155	4.346	4.841	4.450
	Median	-3.00	-3.00	-3.00	-3.00
	Min	-18.00	-21.00	-19.00	-21.00
	Max	3.00	3.00	5.00	5.00
Day8	n	69	71	70	210
	Mean	-2.77	-2.69	-1.90	-2.45
	SD	4.678	4.967	7.161	5.698
	Median	-2.00	-2.00	-1.00	-2.00
	Min	-18.00	-20.00	-32.00	-32.00
	Max	10.00	9.00	23.00	23.00

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)

**Table 14.3.4.1.2.2**  
**PF-06410293 Protocol B5381001**  
**Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set**  
**Parameter: Aspartate Aminotransferase (U/L)**

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
<b>Study Day</b>					
Day15	n	68	71	69	208
	Mean	-0.84	9.70	-1.58	2.51
	SD	5.576	85.855	7.455	50.477
	Median	-1.00	-1.00	-1.00	-1.00
	Min	-17.00	-15.00	-31.00	-31.00
	Max	16.00	719.00	20.00	719.00
Day29	n	67	70	70	207
	Mean	-0.01	3.11	4.41	2.54
	SD	6.866	10.999	30.028	19.002
	Median	1.00	1.00	0.00	1.00
	Min	-17.00	-15.00	-34.00	-34.00
	Max	35.00	62.00	228.00	228.00
Day43	n	67	71	69	207
	Mean	1.37	2.79	3.01	2.41
	SD	6.685	10.307	16.103	11.685
	Median	1.00	0.00	1.00	1.00
	Min	-17.00	-13.00	-32.00	-32.00
	Max	33.00	61.00	95.00	95.00

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)

**Table 14.3.4.1.2.2**  
**PF-06410293 Protocol B5381001**  
**Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set**  
**Parameter: Aspartate Aminotransferase (U/L)**

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
<b>Study Day</b>					
Day71	n	69	71	70	210
	Mean	1.86	3.04	3.87	2.93
	SD	5.364	7.846	23.836	14.773
	Median	2.00	2.00	2.00	2.00
	Min	-10.00	-17.00	-28.00	-28.00
	Max	21.00	35.00	183.00	183.00

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)



**Table 14.3.4.1.2.2**  
**PF-06410293 Protocol B5381001**  
**Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set**  
**Parameter: Alanine Aminotransferase (U/L)**

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
<b>Study Day</b>					
Baseline	n	69	71	70	210
	Mean	21.90	25.58	24.51	24.01
	SD	8.347	13.762	8.970	10.726
	Median	21.00	23.00	24.00	23.00
	Min	5.00	9.00	11.00	5.00
	Max	41.00	75.00	62.00	75.00
Day4	n	69	71	70	210
	Mean	-1.36	-2.03	-1.13	-1.51
	SD	5.230	4.326	5.561	5.052
	Median	-2.00	-2.00	-1.00	-1.00
	Min	-17.00	-14.00	-24.00	-24.00
	Max	18.00	9.00	10.00	18.00
Day8	n	69	71	70	210
	Mean	0.75	0.59	2.26	1.20
	SD	7.651	8.006	10.163	8.671
	Median	0.00	1.00	2.00	1.00
	Min	-19.00	-20.00	-29.00	-29.00
	Max	25.00	27.00	55.00	55.00

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)

**Table 14.3.4.1.2.2**  
**PF-06410293 Protocol B5381001**  
**Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set**  
**Parameter: Alanine Aminotransferase (U/L)**

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
<b>Study Day</b>					
Day15	n	68	71	69	208
	Mean	0.78	6.55	0.51	2.66
	SD	7.786	35.521	10.421	22.133
	Median	1.00	2.00	1.00	1.00
	Min	-24.00	-18.00	-37.00	-37.00
	Max	28.00	285.00	47.00	285.00
Day29	n	67	70	70	207
	Mean	1.28	4.34	3.70	3.14
	SD	8.043	10.693	26.758	17.337
	Median	1.00	2.00	0.00	1.00
	Min	-23.00	-21.00	-28.00	-28.00
	Max	29.00	46.00	201.00	201.00
Day43	n	67	71	69	207
	Mean	1.45	3.15	2.26	2.30
	SD	6.959	9.353	12.579	9.897
	Median	1.00	3.00	2.00	2.00
	Min	-12.00	-14.00	-30.00	-30.00
	Max	32.00	32.00	78.00	78.00

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)

**Table 14.3.4.1.2.2**  
**PF-06410293 Protocol B5381001**  
**Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set**  
**Parameter: Alanine Aminotransferase (U/L)**

		<b>Adalimumab-Pfizer (N=69)</b>	<b>Adalimumab-US (N=71)</b>	<b>Adalimumab-EU (N=70)</b>	<b>Total (N=210)</b>
<b>Study Day</b>					
Day71	n	69	71	70	210
	Mean	1.35	3.99	3.29	2.89
	SD	7.306	9.507	19.386	13.151
	Median	1.00	3.00	2.00	2.00
	Min	-13.00	-15.00	-29.00	-29.00
	Max	22.00	33.00	139.00	139.00

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)